Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

NCT07454915 is registered in ClinicalTrials.gov with PapiVax Biotech, Inc. as lead sponsor.

NCT NCT07454915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07454915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
Lead sponsor
PapiVax Biotech, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2026
Completion date
June 30, 2028
Enrollment
138 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia grade 2/3, human papilloma virus infection type 16